EXHIBIT 12.1

Ratio of Earnings to Fixed Charges
(dollars in thousands, except ratio data)

	Year Ended December 31,
	2004			2003			2002			2001			2000
Fixed Charges:
Interest expense on indebtedness (including amortization of debt expense and discount)	$	22,868		$	23,723		$	23,746		$	24,638		$	22,088
Interest expense on portion of rent expense representative of interest		9,089			7,604			7,206			6,159			3,251
Total Fixed Charges	$	31,957		$	31,327		$	30,952		$	30,797		$	25,339
Earnings (Loss):
Net loss before provision for income taxes and cumulative effect of change in accounting principle	$	(242,898	)	$	(185,324	)	$	(219,716	)	$	(117,152	)	$	(235,331	)
Fixed Charges per above		31,957			31,327			30,952			30,797			25,339
Total Earnings (Loss)	$	(210,941	)	$	(153,997	)	$	(188,764	)	$	( 86,355	)	$	(209,992	)
Ratio of Earnings to Fixed Charges		—			—			—			—			—
Coverage deficiency (1)(2)(3)(4)	$	(242,898	)	$	(185,324	)	$	(219,716	)	$	(117,152	)	$	(235,331	)

(1)   The Company’s Coverage deficiency for 2004 includes net charges of $12,975, relating to a $15,408 charge for restructuring partially offset by a gain recognized on the extinguishment of debt of $2,433.

(2)   The Company’s Coverage deficiency for 2002 includes charges aggregating $46,396 arising from the Company’s impairment charge relating to its investment in CAT and a charge for construction design changes of $32,158 and $14,238, respectively.

(3)   The Company’s Coverage deficiency for 2001 includes charges aggregating $26,208 arising from the Company’s impairment charge relating to its investment in Transgene and debt conversion expenses of $22,314 and $3,894, respectively.

(4)   The Company’s Coverage deficiency for 2000 includes charges aggregating $184,868 arising from purchased in-process research and development and debt conversion expenses of $134,050 and $50,818, respectively.